SAB Biotherapeutics (SABS) Non Operating Interest Expenses (2021 - 2026)
Powered by 
Analysis
SAB Biotherapeutics (SABS) Non Operating Interest Expenses (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 20.27 Mn |
| 10 | SAB Biotherapeutics | 295.88 Mn | 295.88 Mn | - | 62,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 62,000.00 |
| Mar 31, 2026 | 62,745.00 |
| Dec 31, 2025 | 63,462.00 |
| Sep 30, 2025 | 43,292.00 |
| Jun 30, 2025 | 64,000.00 |
| Mar 31, 2025 | 69,565.00 |
| Dec 31, 2024 | 70,876.00 |
| Sep 30, 2024 | 78,036.00 |
| Jun 30, 2024 | 93,119.00 |
| Mar 31, 2024 | 76,371.00 |
| Dec 31, 2023 | 77,879.00 |
| Sep 30, 2023 | 69,700.00 |
| Jun 30, 2023 | 75,320.00 |
| Mar 31, 2023 | 92,385.00 |
| Dec 31, 2022 | 87,699.00 |
| Sep 30, 2022 | 70,626.00 |
| Jun 30, 2022 | 71,237.00 |
| Mar 31, 2022 | 72,022.00 |
| Dec 31, 2021 | 66,275.00 |
| Sep 30, 2021 | 78,558.00 |